International Journal of Radiation Oncology * Biology * Physics
Volume 72, Issue 2 , Pages 597-604, 1 October 2008

The Observed Variance Between Predicted and Measured Radiation Dose in Breast and Prostate Patients Utilizing an In Vivo Dosimeter

  • Charles W. Scarantino, M.D., Ph.D.

      Affiliations

    • Sicel Technologies Inc., Morrisville, NC
    • Department of Radiation, Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, VA
    • Corresponding Author InformationReprint requests to: Charles W. Scarantino M.D., Ph.D., Department of Radiation Oncology, Rex Cancer Center, 4420 Lake Boone Trail, Raleigh, NC 27607. Tel: (919) 784-3018; Fax: (919) 783-0737
    • ,
  • Bradley R. Prestidge, M.D.

      Affiliations

    • Texas Cancer Clinic, San Antonio, TX
    • ,
  • Mitchel S. Anscher, M.D.

      Affiliations

    • Department of Radiation Oncology, Rex Cancer Center, Raleigh, NC
    • ,
  • Carolyn R. Ferree, M.D.

      Affiliations

    • Department of Radiation Oncology, Wake Forest University, Bowman Gray Campus, Winston-Salem, NC
    • ,
  • William T. Kearns, M.S.

      Affiliations

    • Department of Radiation Oncology, Wake Forest University, Bowman Gray Campus, Winston-Salem, NC
    • ,
  • Robert D. Black, Ph.D.

      Affiliations

    • Sicel Technologies Inc., Morrisville, NC
    • ,
  • Natasha G. Bolick, M.S.

      Affiliations

    • Sicel Technologies Inc., Morrisville, NC
    • ,
  • Gloria P. Beyer, Ph.D.

      Affiliations

    • Sicel Technologies Inc., Morrisville, NC

Received 17 December 2007; received in revised form 27 May 2008; accepted 30 May 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Conflict of Interest: The following participants are associated with Sicel Technologies, Inc., the manufacturer of the implantable dosimeter used in the study: Charles W. Scarantino, M.D., Ph.D., is a cofounder of the company, medical director for the company, and member of the Board of Directors; Gloria P. Beyer, Ph.D., is an officer of the company; Robert D. Black, Ph.D., was an officer of the company during the study and a consultant for the company at the time of data analysis; Natasha Bolick is an employee of the company.

 The study analyzes the data obtained from a Food and Drug Administration–approved study protocol. The data used and presented in this research were collected, monitored, and managed in accordance with the FDA's adopted ICH Guideline for Good Clinical Practice and 21 CFR Parts 50, 54, 56, and 812 and 45 CFR Parts 160 and 164.

 Supported in part by NCI Grant R21CA 97859.

PII: S0360-3016(08)02465-6

doi:10.1016/j.ijrobp.2008.05.058

International Journal of Radiation Oncology * Biology * Physics
Volume 72, Issue 2 , Pages 597-604, 1 October 2008

Article Tools

* Image Usage & Resolution